Loading...
•
Sep 30, 2022
Insmed Q3 2022 Earnings Report
Insmed experienced revenue growth and advanced clinical programs.
Key Takeaways
Insmed reported a 45% year-over-year increase in ARIKAYCE revenue for Q3 2022, reaching $67.7 million. The company is progressing with clinical trials and secured financing to support its four pillars. Insmed reported a net loss of $131.1 million, or $1.09 per share.
ARIKAYCE revenue grew 45% year-over-year, reaching $67.7 million in Q3 2022.
ARIKAYCE net sales were $49.5 million in the U.S., $14.5 million in Japan, and $3.7 million in Europe and rest of world.
Enrollment remains on track for the Phase 3 ASPEN study of brensocatib, with topline data expected in Q2 2024.
Strategic financings increased cash and cash equivalents and marketable securities to approximately $1.3 billion.
Insmed
Insmed
Forward Guidance
Insmed expects full-year 2022 global revenues for ARIKAYCE to increase at least 30% year over year from 2021.
Positive Outlook
- Commercialization and expansion of ARIKAYCE globally
- Advancement of brensocatib, including the Phase 3 ASPEN study in patients with bronchiectasis and commercial launch readiness activities
- Advancement of the confirmatory, frontline clinical trial program for ARIKAYCE (ARISE and ENCORE)
- Advancement of our earlier-stage pipeline, including the Phase 2 clinical development programs for TPIP
- Advancing our translational medicine efforts